[Effect of gestagen therapy on clinical and biochemical parameters in patients with atypical endometrial hyperplasia]. 2000

O V Makarov, and P V Sergeev, and N K Sviridov, and E N Kareva, and E G Isaeva, and K K Mgdesian, and N V Kirpichnikova
Russian State Medical University, Moscow.

The investigation involved 22 reproductive and menopausal women (aged 30-48) with atypical endometrial hyperplasia. In addition to general clinical examination, all the patients underwent ultrasound scanning of the organs of the small pelvis, hysteroscopy and diagnostic curettage for morphological examination both before and after treatment. All tissue samples taken before and after treatment were assayed for cytoplasmic and plasma-membrane receptor levels and a number of biochemical parameters of plasma membranes. Hormone therapy with prolonged-release gestagen-based drugs pointed to changes which occurred in: (1) sex steroid reception at cytosol and plasma-membrane levels; (2) the lipids profile of plasma membranes, and (3) activity of membrane-related enzymes. Among the beneficial results of gestagen treatment was coming most of lipid profile parameters and plasma-membrane enzymes back to normal. However, a decrease in the progesterone reception level in target tissue after 3-6 month treatment may suggest a likelihood of development of tolerance to gestagen. The data also suggest that further research continue in this area of endometrial precancer.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011372 Progestins Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY. Gestagenic Agent,Progestagen,Progestagenic Agent,Progestational Agent,Progestational Compound,Progestational Hormone,Progestogen,Progestogens,Gestagen,Gestagen Effect,Gestagen Effects,Gestagenic Agents,Gestagenic Effect,Gestagenic Effects,Gestagens,Progestagenic Agents,Progestagens,Progestational Agents,Progestational Compounds,Progestational Hormones,Progestin,Progestin Effect,Progestin Effects,Progestogen Effect,Progestogen Effects,Agent, Gestagenic,Agent, Progestagenic,Agent, Progestational,Compound, Progestational,Effect, Gestagen,Effect, Gestagenic,Effect, Progestin,Effect, Progestogen,Effects, Gestagen,Effects, Gestagenic,Effects, Progestin,Effects, Progestogen,Hormone, Progestational
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D003600 Cytosol Intracellular fluid from the cytoplasm after removal of ORGANELLES and other insoluble cytoplasmic components. Cytosols
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D004714 Endometrial Hyperplasia Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant. Atypical Endometrial Hyperplasia,Complex Endometrial Hyperplasia,Simple Endometrial Hyperplasia,Atypical Endometrial Hyperplasias,Complex Endometrial Hyperplasias,Endometrial Hyperplasia, Atypical,Endometrial Hyperplasia, Complex,Endometrial Hyperplasia, Simple,Endometrial Hyperplasias,Endometrial Hyperplasias, Atypical,Endometrial Hyperplasias, Complex,Endometrial Hyperplasias, Simple,Hyperplasia, Atypical Endometrial,Hyperplasia, Complex Endometrial,Hyperplasia, Endometrial,Hyperplasia, Simple Endometrial,Hyperplasias, Atypical Endometrial,Hyperplasias, Complex Endometrial,Hyperplasias, Endometrial,Hyperplasias, Simple Endometrial,Simple Endometrial Hyperplasias
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

O V Makarov, and P V Sergeev, and N K Sviridov, and E N Kareva, and E G Isaeva, and K K Mgdesian, and N V Kirpichnikova
October 2022, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences,
O V Makarov, and P V Sergeev, and N K Sviridov, and E N Kareva, and E G Isaeva, and K K Mgdesian, and N V Kirpichnikova
April 1958, Geburtshilfe und Frauenheilkunde,
O V Makarov, and P V Sergeev, and N K Sviridov, and E N Kareva, and E G Isaeva, and K K Mgdesian, and N V Kirpichnikova
September 2005, European journal of obstetrics, gynecology, and reproductive biology,
O V Makarov, and P V Sergeev, and N K Sviridov, and E N Kareva, and E G Isaeva, and K K Mgdesian, and N V Kirpichnikova
October 2014, Anticancer research,
O V Makarov, and P V Sergeev, and N K Sviridov, and E N Kareva, and E G Isaeva, and K K Mgdesian, and N V Kirpichnikova
January 1991, Akusherstvo i ginekologiia,
O V Makarov, and P V Sergeev, and N K Sviridov, and E N Kareva, and E G Isaeva, and K K Mgdesian, and N V Kirpichnikova
September 1970, Deutsche medizinische Wochenschrift (1946),
O V Makarov, and P V Sergeev, and N K Sviridov, and E N Kareva, and E G Isaeva, and K K Mgdesian, and N V Kirpichnikova
February 1966, Ceskoslovenska gynekologie,
O V Makarov, and P V Sergeev, and N K Sviridov, and E N Kareva, and E G Isaeva, and K K Mgdesian, and N V Kirpichnikova
March 2022, Zhonghua zhong liu za zhi [Chinese journal of oncology],
O V Makarov, and P V Sergeev, and N K Sviridov, and E N Kareva, and E G Isaeva, and K K Mgdesian, and N V Kirpichnikova
March 1959, Obstetrics and gynecology,
O V Makarov, and P V Sergeev, and N K Sviridov, and E N Kareva, and E G Isaeva, and K K Mgdesian, and N V Kirpichnikova
March 1964, Toko-ginecologia practica,
Copied contents to your clipboard!